Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
CAMBRIDGE, Mass., Feb. 18, 2016 -- Proteostasis Therapeutics, Inc. today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share. All of the shares sold in the offering were offered by Proteostasis Therapeutics, Inc. The company’s shares began trading on the NASDAQ Global Market on February 11, 2016 under the ticker symbol “PTI.” The gross proceeds from the offering are $50.0 million, before deducting underwriting discounts and commissions and expenses associated with the offering payable by the company.
Leerink Partners and RBC Capital Markets acted as joint book-running managers. Baird and H.C. Wainwright & Co. acted as co-managers.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on February 10, 2016. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at (800) 808-7525, ext. 6142; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, Telephone: (877) 822-4089, Email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact: Dan Budwick, Pure Communications [email protected] 973-271-6085 Investor Contact: Luke Heagle, Pure Communications [email protected] 910-726-1372
